Aptamer Sciences
압타머사이언스 · 291650
Industrials Commercial Services · KOSDAQ
Market cap US$40.8M (₩56.3B)
Overview
Aptamer Sciences is a South Korean biotech listed on KOSDAQ that develops cancer treatments and diagnostic tools built around aptamers, short, lab-engineered molecules that bind tightly to specific biological targets, similar in concept to antibodies.
Its lead drug-development platform, called ApDC®, links aptamers to cancer-killing agents to create targeted therapies for solid and blood cancers, which the company aims to license out to larger pharmaceutical partners after establishing clinical proof of concept. Alongside drug development, it provides analytical testing services for biopharmaceuticals, including antibody drugs and peptides, to pharma companies and biotech ventures, and holds a diagnostic product designed to assess lung-cancer risk from blood protein markers.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$176.2K
- FY2024US$784.6K
- FY2025US$2.5M
Operating profit
- FY2023−US$8.8M
- FY2024−US$5.1M
- FY2025−US$5.7M
Net income
- FY2023−US$9.9M
- FY2024−US$6.3M
- FY2025−US$6.2M
Key ratios (FY2025)
Why it matters
The company was spun off from POSTECH, a South Korean research university, and entered the contract research services business through a merger completed in the most recent filing period.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?